---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009512"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2023-05-12T23:59:59+00:00"
generated_at: "2026-06-15T02:36:06.495537+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# NeuroBo appoints Mark A. Glickman to board of directors

## Summary
- Appointed effective May 11, 2023 as Class III director, term expiring at 2025 annual meeting.
- Glickman brings over 30 years pharma experience; most recently co-CEO of TherapeuticsMD (TXMD).
- Will receive standard non-employee director compensation: initial 40,000-share option grant and $40,000 annual cash retainer (pro-rated for 2023).
- Company plans Q3 2023 Phase 2a trial for DA-1241 (NASH) and IND for DA-1726 (GLP1R/GCGR) with Phase 1a in H1 2024.
- No family relationships or material arrangements with any other director or officer.

## SEC filing metadata
- accession: 0001558370-23-009512
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2023-05-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837023009512/0001558370-23-009512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837023009512/nrbo-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009512
- JSON: https://secwatch.observer/filing/0001558370-23-009512.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009512.txt

## Key facts
- Executive change
  Mark A. Glickman was appointed as Class III director at MetaVia Inc..
  - Action: appointed
  - Role: Class III director
  source text: On May 11, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc., a Delaware corporation (the “Company” ), on the recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee” ), appointed Mark A. Glickman, effective immediately, to serve as a Class III director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1638287/000155837023009512/0001558370-23-009512-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.